Clinical Trial: A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC (China)

China, Aug. 13 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129986

Registration Time: 2026/08/12

Type: Interventional study

Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337505

Published by HT Digital Content Services with permission from Health Daily Digest....